Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors

Article (Faculty180)

cited authors

  • Yang, Tao; Mei, Xue; Tackie-Yarboi, Ethel; Akere, Millicent Tambar T; Kyoung, Jun; Mell, Blair; Yeo, Ji-You Y; Cheng, Xi; Zubcevic, Jasenka; Richards, Elaine M; Pepine, Carl J; Raizada, Mohan K; Schiefer, Isaac T; Joe, Bina

description

  • <p><em>This work is the first mechanistic study in the pharmacomicrobiomics field testing the antihypertensive medication. It shows how a gut microbe can inactivate a cardiovascular drug in vivo, with early human data suggesting possible links to population differences in drug responsiveness. The findings highlight the potential for microbiome-based precision medicine, where gut microbial composition could guide the selection of antihypertensive therapy to improve treatment outcomes. This paper has broad media coverage in NHLBI, EurakAlert!, PhillyVoice, etc. It has been cited 43 times from its online Aug 2022 to Aug 2025.</em></p>

authors

publication date

  • 2022

published in

start page

  • 1591

end page

  • 1601

volume

  • 79